Emerging Protein and Peptide Therapeutics for Osteoporosis: Advances in Anabolic and Catabolic Treatments

Simple item page
dc.contributor.authorKuril, AKen_US
dc.contributor.authorManchuri, KMen_US
dc.contributor.authorAnand, SP.en_US
dc.date.accessioned2024-12-02T10:01:38Z
dc.date.available2024-12-02T10:01:38Z
dc.date.issued2024-10
dc.description.abstractOsteoporosis is a prevalent skeletal disorder characterized by reduced bone density and increased fracture risk, primarily affecting the elderly population. The pathophysiology of osteoporosis involves an imbalance between bone resorption and bone formation, with catabolic processes (bone breakdown) counteracting anabolic processes (bone formation). Treatment strategies for osteoporosis are categorized into anabolic and catabolic approaches, each targeting different aspects of bone metabolism. Catabolic treatments focus on inhibiting bone resorption. peptides, such as Calcitonin Salmon and monoclonal antibodies like denosumab, inhibit osteoclast activity, thereby reducing bone turnover. These catabolic agents effectively stabilize bone density and reduce the incidence of fractures, especially in postmenopausal women. Anabolic treatments aim to stimulate bone formation, thereby increasing bone mass and improving bone microarchitecture. Teriparatide, a recombinant form of parathyroid hormone, and abaloparatide, a synthetic analog, and monoclonal antibody romosozumab are the primary anabolic agents. These drugs activate osteoblasts, enhancing bone formation and leading to significant improvements in bone density and reduction in fracture risk. Combining anabolic and catabolic therapies has shown promise in optimizing bone health, as it addresses both aspects of the bone remodeling process. Recent studies have shown that PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) can limit bone loss and improve bone density in animal models of menopause by acting straightly on osteoblasts, the cells responsible for formation of bone, via NCAM-1 signaling, promoting their maturation and new bone formation (anabolic). Bioactive collagen peptides have shown promise as a treatment for osteoporosis by improving bone mineral density (BMD) and supporting overall bone health.en_US
dc.identifier.affiliationsBhagwant University, Sikar Road, Ajmer, Rajasthan, Indiaen_US
dc.identifier.affiliationsDepartment of Chemistry, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, Andhra Pradesh, 515002, Indiaen_US
dc.identifier.affiliationsSchool of Medicine American University of Barbados, Wildey, Saint Michael, BB- 11064, Barbados.en_US
dc.identifier.citationKuril AK, Manchuri KM, Anand SP.. Emerging Protein and Peptide Therapeutics for Osteoporosis: Advances in Anabolic and Catabolic Treatments. Journal of Pharmaceutical Research International. 2024 Oct; 36(11): 85-102en_US
dc.identifier.issn2456-9119
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/239492
dc.languageenen_US
dc.publisherMs. M. B. Mondalen_US
dc.relation.issuenumber11en_US
dc.relation.volume36en_US
dc.source.urihttps://doi.org/10.9734/jpri/2024/v36i117603en_US
dc.subjectPostmenopausal osteoporosisen_US
dc.subjectteriparatideen_US
dc.subjectdenosumaben_US
dc.subjectabaloparatideen_US
dc.subjectromosozumaben_US
dc.subjectcalcitonin salmonen_US
dc.titleEmerging Protein and Peptide Therapeutics for Osteoporosis: Advances in Anabolic and Catabolic Treatmentsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jpri2024v36n11p85.pdf
Size:
751.57 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmaceutical Research International